Benchmark Upgrades Cryolife To Buy, $6.50 PT

The Benchmark Company has upgraded Cryolife CRY from Hold to Buy and has established a $6.50 price target.
Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Posted In: UpgradesPrice TargetAnalyst RatingsHealth CareHealth Care EquipmentThe Benchmark Company
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!